Region selection based TOO accuracy measurement for COOBoostR. (a,b) TOO prediction accuracy for BM and EAC derived from different study sources. In each case, TOO prediction accuracy was again measured by utilizing 1-megabase regions containing gastric specific enhancers or squamous specific enhancers. BM: Barrett’s metaplasia; EAC: Esophageal adenocarcinoma. (c) Region selection based COOBoostR accuracy measurement ranging from 500 to 1000 regions for 8 sample types (7 cancer types, 1 precancerous lesion) at aggregated sample level. (d) Region selection analysis with respect to the portion of gastric/squamous specific enhancer containing regions for EACs at individual sample level. Enhancer inclusion ratio was varying from 0 to 100%, making up to 100 regions [2,3,4,6,7,8].